<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="368691">
  <stage>Registered</stage>
  <submitdate>9/11/2015</submitdate>
  <approvaldate>19/11/2015</approvaldate>
  <actrnumber>ACTRN12615001268538</actrnumber>
  <trial_identification>
    <studytitle>Comparison of the absorption of magnesium citrate and magnesium oxide in healthy subjects.</studytitle>
    <scientifictitle>Bioavailability of organic magnesium (magnesium citrate) versus inorganic magnesium (magnesium oxide)  A single-center, randomized, 2-supplementation, 2-period, 2-sequence, single-dose, cross-over study in healthy male subjects.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Absorption of magnesium.</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>20 healthy male subjects are randomized to receive an oral single-dose of magnesium citrate (equivalent to 300 mg magnesium) or magnesium oxide (equivalent to 300 mg magnesium) in a cross-over design with a 3 day wash-out period under supervision of the investigators.</interventions>
    <comparator>The control is magnesium oxide.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Amount of magnesium excreted into the urine.
</outcome>
      <timepoint>Timepoint: within 24 h after intervention.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Magnesium concentration in monocytes/lymphocytes (explorative evaluation).</outcome>
      <timepoint>Timepoints: predose, 9 h and 24 h post dose.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Magnesium concentration in erythrocytes (explorative evaluation).</outcome>
      <timepoint>Predose, 9 h and 24 h post dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Magnesium concentration in serum (explorative evaluation).</outcome>
      <timepoint>Predose, 60 min, 2 h, 3 h, 4 h, 5 h, 6 h, 9 h and 24 h post dose.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Male Caucasians aged between 18 and 45 years (including) in general good physical health and normal weight with normal renal function.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Any illnesses or medication with influence on renal function.
More than moderate alcohol consumption or history of alcohol abuse.
Supplementation with magnesium.
Symptoms of magnesium deficiency.
Any gastrointestinal complaints.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>19/06/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate>26/06/2015</actualenddate>
    <samplesize>20</samplesize>
    <actualsamplesize>20</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bavaria</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Verla-Pharm Arzneimittel</primarysponsorname>
    <primarysponsoraddress>Hauptstrasse 98
82327 Tutzing</primarysponsoraddress>
    <primarysponsorcountry>Germany</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Verla-Pharm Arzneimittel</fundingname>
      <fundingaddress>Hauptstrasse 98
82327 Tutzing</fundingaddress>
      <fundingcountry>Germany</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a randomized, controlled, cross-over study to investigate the absorption and pharmacokinetics of magnesium citrate compared with magnesium oxide after a single oral dose of magnesium. The primary outcome is the amount of magnesium excreted into the urine. The magnesium concentration in monocytes/lymphocytes and erythrocytes serve as secondary outcomes. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethikkommission der Bayerischen Landesaerztekammer</ethicname>
      <ethicaddress>Muehlbaurstrasse 16, 81677 MÃ¼nchen</ethicaddress>
      <ethicapprovaldate>27/04/2015</ethicapprovaldate>
      <hrec>15030</hrec>
      <ethicsubmitdate />
      <ethiccountry>Germany</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Mr</title>
      <name>Dominik Kappeler</name>
      <address>Inamed (contract research organization)
Robert-Koch-Allee 29, 82131 Gauting</address>
      <phone>+49 89 893 569-28</phone>
      <fax />
      <email>d.kappeler@inamed-cro.com</email>
      <country>Germany</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Dominik Kappeler</name>
      <address>Inamed (contract research organization)
Robert-Koch-Allee 29, 82131 Gauting</address>
      <phone>+49 89 893 569-28</phone>
      <fax />
      <email>d.kappeler@inamed-cro.com</email>
      <country>Germany</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Dominik Kappeler</name>
      <address>Inamed (contract research organization)
Robert-Koch-Allee 29, 82131 Gauting</address>
      <phone>+49 89 893 569-28</phone>
      <fax />
      <email>d.kappeler@inamed-cro.com</email>
      <country>Germany</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>